FDA’s concerns with unapproved GLP-1 drugs used for weight loss
5 settembre 2025
Leggi
EMA: warning about sharp rise in illegal medicines sold in the EU
3 settembre 2025
Leggi
AIFA: allerta sull’aumento di farmaci illegali venduti nell’UE come agonisti del recettore del GLP-1
4 settembre 2025
Leggi
AIFA: nota Informativa Importante su Victoza: rischio di carenza a causa della cessazione della commercializzazione (interruzione)
5 settembre 2025
Leggi
AIFA: modifiche monitoraggio LEQVIO e passaggio a PIANO TERAPEUTICO WEB-BASED
4 settembre 2025
Leggi
The selection and use of essential medicines, 2025: report of the 25th WHO Expert Committee on Selection and Use of Essential Medicines, executive summary.
5 settembre 2025
Leggi
Advancing type 1 diabetes management: integrating novel therapies, technologies, and adjunctive approaches
Snaith JR, Narongkiatikhun P, Bjornstad P, et al.
Diabetes Care. Pub. online 29 Aug 2025.
Leggi
Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction
Krüger N, Schneeweiss S, Fuse K, et al.
JAMA. 2025:e2514092.
Leggi
Glycaemic control after connected insulin pen initiation in people living with diabetes: results from a real-world setting
Adolfsson P, Guerci B, Hartvig NV, et al.
Diabetes Obes Metab. Pub. online 28 Aug 2025.
Leggi
Comparison of an energy-reduced mediterranean diet and physical activity versus an ad libitum mediterranean diet in the prevention of type 2 diabetes : a secondary analysis of a randomized controlled trial
Ruiz-Canela M, Corella D, Martínez-González MÁ, et al.
Ann Intern Med. Pub. online 26 Aug 2025.
Leggi